Fc Engineering Overview

The human IgG1 (EN) Fc variant is an ultra-silent, multi-residue chimeric effector-null backbone based on the Armour paradigm. By transplanting sequence elements from non-effector human IgG2 and IgG4 subclasses into the IgG1 lower hinge (E233P/L234V/L235A/ΔG236) and CH2 complement loop (A327G/A330S/P331S), EN completely abolishes all FcγR engagement (FcγRI, IIa, IIb, IIIa) and C1q complement activation. It serves as Fusion BioLabs’ premier ultra-silent chimeric option.

Functional Profile

Mechanism of Action

The EN variant employs a dual-subdomain chimeric substitution strategy within the lower hinge and CH2 domain:

• Lower Hinge Silencing (E233P/L234V/L235A/ΔG236): Replaces the IgG1 lower hinge with the corresponding IgG2 sequence motif (PVA) and deletes Glycine 236. This eliminates the flexible hydrophobic ridge required for high-affinity FcγRI (CD64) and low-affinity FcγRII/III binding.
• CH2 Loop Silencing (A327G/A330S/P331S): Replaces IgG1 residues with IgG4/IgG2 equivalents in the Proline 331 loop. This disrupts the globular head C1q binding interface and prevents complement activation.
• Combined Effect: Dual-level disruption resulting in complete effector silencing while retaining full endosomal FcRn recycling and wild-type N297 glycosylation.

Phenotypic Effects

• Complete absence of NK cell-mediated ADCC, macrophage ADCP, and antibody-dependent cellular phagocytosis.
• Total loss of C1q binding and classical complement cascade activation (CDC-null).
• Zero detectable binding across all human Fcγ receptor classes.
• Preserves standard IgG1 pharmacokinetic half-life and endosomal recycling in vivo.
• Retains native N297 glycosylation, biophysical solubility, and high production yield.

Applications

• Safety-critical therapeutic antibodies where zero effector activity or Fc-mediated cytokine release is required.
• Immune checkpoint blockers (anti-PD-1, anti-PD-L1, anti-TIGIT, anti-CTLA-4) targeting cell-surface receptors on delicate immune populations.
• Agonist antibodies requiring pure target engagement without Fc receptor cross-linking.
• Multispecific and bispecific formats requiring an ultra-silent, non-immunogenic Fc backbone.
• Primary comparative reference for testing multi-residue sequence replacements against proline-sandwich variants (LALA-PG).

Plasmid Map & Feature Annotation

Insert Structure: VH – CH1 – hinge(E233P/L234V/L235A/ΔG236) – CH2(A327G/A330S/P331S) – CH3(WT)

• VH: Variable heavy domain
• CH1: Constant heavy 1
• Hinge: Native IgG1 core hinge
• Lower Hinge (E233P/L234V/L235A/ΔG236): IgG2-derived lower hinge substitution and deletion
• CH2 (A327G/A330S/P331S): CH2 complement loop substitutions (retains native N297 glycan)
• CH3 (WT): Native IgG1 CH3 domain

Fusion BioLabs EffectorNull Family Comparison Matrix

Storage & Handling

• Plasmid: Store at −20°C.
• Purified Antibody: Store at 2–8°C for short-term storage; −80°C for long-term storage.
• Avoid repeated freeze–thaw cycles.
• Use sterile technique for all handling.

References

1. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol. 1999;29(8):2613-2624.
2. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164(8):4178-4184.
3. Armour KL, van de Winkel JG, Williamson LM, Clark MR. Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol. 2003;40(9):585-593.